Extensively drug-resistant tuberculosis in the United States, 1993-2007

JAMA

Volumn 300, Issue 18, 2008, Pages 2153-2160

  Shah, N Sarita ^a,b   Pratt, Robert ^a   Armstrong, Lori ^a   Robison, Valerie ^a   Castro, Kenneth G ^a   Cegielski, J Peter ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CAPREOMYCIN; ISONIAZID; KANAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMYCIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DRUG SENSITIVITY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; NEWBORN; PRIORITY JOURNAL; RISK FACTOR; SPUTUM CULTURE; TREATMENT OUTCOME; TUBERCULOSIS; UNITED STATES; AIDS RELATED COMPLEX; COMPARATIVE STUDY; DIRECTLY OBSERVED THERAPY; HEALTH SURVEY; MIDDLE AGED; MORTALITY; PRESCHOOL CHILD; SOCIOECONOMICS; SURVIVAL;

ADOLESCENT; ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; DIRECTLY OBSERVED THERAPY; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; RISK FACTORS; SOCIOECONOMIC FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; UNITED STATES;

EID: 56149108209     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.300.18.2153     Document Type: Article

References (40)

1. World Health Organization. Global Tuberculosis Control - Surveillance, Planning, Financing: WHO Report 2008. Geneva, Switzerland: World Health Organization; 2008. Document WHO/HTM/TB/2008.393.
2. World Health Organization. Anti-Tuberculosis Drug Resistance in the World: Fourth Global Report. Geneva, Switzerland: World Health Organization; 2008.
3. Zignol M, Hosseini MS, Wright A, et al. Global incidence of multidrug-resistant tuberculosis. J Infect Dis. 2006;194(4):479-485.
4. Nathanson E, Lambregts-van WC, Rich ML, et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect Dis. 2006;12(9):1389-1397.
5. Rajbhandary SS, Marks SM, Bock NN. Costs of patients hospitalized for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2004;8(8):1012-1016.
6. Ward HA, Marciniuk DD, Hoeppner VH, Jones W. Treatment outcome of multidrug-resistant tuberculosis among Vietnamese immigrants. Int J Tuberc Lung Dis. 2005;9(2):164-169.
7. Centers for Disease Control and Prevention. Multidrug-resistant tuberculosis in Hmong refugees resettling from Thailand into the United States, 2004-2005. MMWR Morb Mortal Wkly Rep. 2005;54(30):741-744.
8. Tupasi TE, Gupta R, Quelapio MI, et al. Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines. PLoS Med. 2006;3(9):e352.
9. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med. 2003;348(2):119-128.
10. Leimane V, Riekstina V, Holtz TH, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet. 2005;365(9456):318-326.
11. Balabanova Y, Ruddy M, Hubb J, et al. Multidrug-resistant tuberculosis in Russia: clinical characteristics, analysis of second-line drug resistance and development of standardized therapy. Eur J Clin Microbiol Infect Dis. 2005;24(2):136-139.
12. Kam KM, Yip CW. Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-plus. Int J Tuberc Lung Dis. 2004;8(6):760-766.
13. Pardini M, Iona E, Varaine F, et al; LONG-DRUG Study Group. Mycobacterium tuberculosis drug resistance, Abkhazia. Emerg Infect Dis. 2005;11(3):501-503.
14. Prammananan T, Arjratanakool W, Chaiprasert A, et al. Second-line drug susceptibilities of Thai multidrug-resistant Mycobacterium tuberculosis isolates. Int J Tuberc Lung Dis. 2005;9(2):216-219.
15. Timperi R, Han LL, Sloutsky A, et al. Drug resistance profiles of Mycobacterium tuberculosis isolates: five years' experience and insight into treatment strategies for MDR-TB in Lima, Peru. Int J Tuberc Lung Dis. 2005;9(2):175-180.
16. Shah NS, Wright A, Bai GH, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis. 2007;13(3):380-387.
17. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368(9547):1575-1580.
18. Kim HR, Hwang SS, Kim HJ, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis. 2007;45(10):1290-1295.
19. Migliori GB, Besozzi G, Girardi E, et al; SMIRA/TBNET Study Group. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J. 2007;30(4):623-626.
20. Migliori GB, Ortmann J, Girardi E, et al; SMIRA/TBNET Study Group. Extensively drug-resistant tuberculosis, Italy and Germany. Emerg Infect Dis. 2007;13(5):780-782.
21. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep. 2006;55(11):301-305.
22. Raviglione MC. Facing extensively drug-resistant tuberculosis - a hope and a challenge. N Engl J Med. 2008;359(6):636-638.
23. Dye C, Espinal MA. Will tuberculosis become resistant to all antibiotics? Proc Biol Sci. 2001;268(1462):45-52.
24. Migliori GB, De Iaco G, Besozzi G, Centis R, Cirillo DM. First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill. 2007;12(5):E070517.1.
25. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City - turning the tide. N Engl J Med. 1995;333(4):229-233.
26. Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med. 2008;359(6):563-574.
27. Snider DE Jr, Castro KG. The global threat of drug-resistant tuberculosis. N Engl J Med. 1998;338(23):1689-1690.
28. Basu S, Andrews JR, Poolman EM, et al. Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study. Lancet. 2007;370(9597):1500-1507.
29. Centers for Disease Control and Prevention. Trends in tuberculosis incidence - United States, 2006. MMWR Morb Mortal Wkly Rep. 2007;56(11):245-250.
30. Curtis AB, McCray E, McKenna M, Onorato IM. Completeness and timeliness of tuberculosis case reporting: a multistate study. Am J Prev Med. 2001;20(2):108-112.
31. Sprinson JE, Lawton ES, Porco TC, Flood JM, Westenhouse JL. Assessing the validity of tuberculosis surveillance data in California. BMC Public Health. 2006;6:217.
32. Thompson ML, Myers JE, Kriebel D. Prevalence odds ratio or prevalence ratio in the analysis of cross sectional data: what is to be done? Occup Environ Med. 1998;55(4):272-277.
33. Centers for Disease Control and Prevention. Extensively drug-resistant tuberculosis - United States, 1993-2006. MMWR Morb Mortal Wkly Rep. 2007;56(11):250-253.
34. Migliori GB, Lange C, Centis R, et al. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur Respir J. 2008;31(6):1155-1159.
35. Albalak R, O'Brien RJ, Kammerer JS, et al. Trends in tuberculosis/human immunodeficiency virus comorbidity, United States, 1993-2004. Arch Intern Med. 2007;167(22):2443-2452.
36. Reid A, Scano F, Getahun H, et al. Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration. Lancet Infect Dis. 2006;6(8):483-495.
37. Pillay M, Sturm AW. Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin Infect Dis. 2007;45(11):1409-1414.
38. Mlambo CK, Warren RM, Poswa X, Victor TC, Duse AG, Marais E. Genotypic diversity of extensively drug-resistant tuberculosis (XDR-TB) in South Africa. Int J Tuberc Lung Dis. 2008;12(1):99-104.
39. National Committee for Clinical Laboratory Standards. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard. Wayne, PA: National Committee for Clinical Laboratory Standards; 2003. NCCLS document M24-A.
40. Blower S, Supervie V. Predicting the future of XDR tuberculosis. Lancet Infect Dis. 2007;7(7):443